INVO Bioscience and NAYA Biosciences Close Merger, Combined Company to Operate as NAYA Biosciences (NASDAQ: NAYA)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 14 2024
0mins
Source: Newsfilter
Merger Announcement: INVO Bioscience has successfully merged with NAYA Biosciences, creating a new entity that will focus on oncology and autoimmune disease treatments while continuing its fertility business. The combined company will operate under the name NAYA Biosciences and trade on NASDAQ with the ticker "NAYA."
Leadership and Future Plans: The merger will be led by Steve Shum as CEO, with Dr. Daniel Teper appointed as President of the combined company. They aim to leverage their existing fertility revenue alongside innovative therapeutics to enhance shareholder value and accelerate the development of clinical-stage assets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
